Candidate mechanisms for capecitabine‐related hand–foot syndrome

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Hand–foot syndrome (HFS) is a limiting toxicity of the widely used fluorouracil (5FU) prodrug capecitabine. • The pharmacological origin of HFS has not been elucidated. • The expression of capecitabine‐metabolizing enzymes thymidine phosphorylase (TP, activ...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2008-07, Vol.66 (1), p.88-95
Main Authors: Milano, Gérard, Etienne‐Grimaldi, Marie‐Christine, Mari, Mireille, Lassalle, Sandra, Formento, Jean‐Louis, Francoual, Mireille, Lacour, Jean‐Philippe, Hofman, Paul
Format: Article
Language:English
Subjects:
Adult
Antimetabolites, Antineoplastic - adverse effects
Biological and medical sciences
Biopsy
Capecitabine
Cell Proliferation - drug effects
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
dihydropyrimidine dehydrogenase
Drug Safety
Female
Fluorouracil - adverse effects
Fluorouracil - analogs & derivatives
Foot Dermatoses - chemically induced
Foot Dermatoses - pathology
Hand Dermatoses - chemically induced
Hand Dermatoses - pathology
hand–foot syndrome
Humans
Ki67
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pilot Projects
skin
Skin Diseases - chemically induced
Skin Diseases - pathology
thymidine phosphorylase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Hand–foot syndrome (HFS) is a limiting toxicity of the widely used fluorouracil (5FU) prodrug capecitabine. • The pharmacological origin of HFS has not been elucidated. • The expression of capecitabine‐metabolizing enzymes thymidine phosphorylase (TP, activating pathway) and dihydropyrimidine dehydrogenase (DPD, catabolic pathway) in the skin of the palm (target tissue for HFS) is unknown. WHAT THIS STUDY ADDS • This pilot study, conducted in healthy volunteers, clearly demonstrated that TP expression is significantly greater in the palm compared with the lower back (control area). • This suggests TP‐facilitated enhanced production of 5FU in the palm that could explain the occurrence of HFS. • This result may support strategies to prevent HFS. AIMS The oral fluoropyrimidine prodrug capecitabine is widely used in oncology. Capecitabine was designed to generate 5FU via the thymidine phosphorylase (TP) enzyme, preferentially expressed in tumoral tissues. Hand–foot syndrome (HFS) is a limiting toxicity of capecitabine. A pilot study on healthy volunteers was conducted in order to test the hypothesis that the occurrence of HFS could be related to tissue‐specific expression of drug‐metabolizing enzymes in the skin of the palm and sole. To this end, the expression of TP (activating pathway), dihydropyrimidine dehydrogenase (DPD, catabolic pathway) and cell proliferation (Ki67) were measured in the skin of the palm (target tissue for HFS) and of the lower back (control area). METHODS Two paired 4‐mm diameter punch biopsy specimens (palm and back) were taken in 12 healthy volunteers. Immunohistochemical analyses were performed on frozen tissues. RESULTS Proliferation rate (Ki67 staining) was significantly higher in epidermal basal cells of the palm compared with the back (P = 0.008). Also, TP and DPD expression were significantly greater in the palm relative to the back (P = 0.039 and 0.012, respectively). TP and Ki67 expression were positively and significantly correlated in the palm. CONCLUSIONS The high proliferation rate of epidermal basal cells in the palm could make them more sensitive to the local action of cytotoxic drugs. TP‐facilitated local production of 5FU in the palm during capecitabine treatment could explain the occurrence of HFS. This observation may support future strategies to limit the occurrence of HFS during capecitabine therapy.
ISSN:0306-5251
1365-2125
DOI:10.1111/j.1365-2125.2008.03159.x